Chris torrence phoremost
WebAt PhoreMost we have built an exceptional team, making us extremely well-placed to deliver on the potential of SITESEEKER® to unlock the therapeutic potential of … WebTorrance Chief Executive Officer, PhoreMost Ltd. About Dr Chris Torrance is a cancer researcher and entrepreneur.
Chris torrence phoremost
Did you know?
WebWe would like to show you a description here but the site won’t allow us. We would like to show you a description here but the site won’t allow us. PhoreMost have developed methods which enable the routine identification and … 6th September 2024 PhoreMost enters multi-project drug target discovery … WebApr 16, 2024 · Dr. Chris Torrance CEO of PhoreMost, said: “We are excited to bring our SITESEEKER technology to this collaboration with Plexxikon and the Cook lab, leading experts in cell signalling pathways. This is an ideal partnership to potentially transform biological insights into the next generation of innovative medicines.”
WebDr Chris Torrance is a cancer researcher and entrepreneur. In 2007 he founded Horizon Discovery to translate advances in human genome editing into a range of research tools and services to accelerate the discovery of … WebPhoreMost’s novel target-identification platform, SITESEEKER, rapidly identifies unexpected or “cryptic” druggable sites across the entire genome, within targets previously considered undruggable, using the inherent …
WebDr Chris Torrance, CEO, PhoreMost, commented: “This partnership represents the ultimate ambition for any collaboration between biology and technology, where the full diversity of newly identified druggable disease targets generated by biological PROTEINi shape-libraries can now be married to the most logical and rapid method of finding … WebChris Torrance is the Co-Founder and CEO at PhoreMost. Additionally, Chris Torrance has had 2 past jobs including Founder and Chief Scientific Officer at Horizon Discovery.
WebMar 23, 2024 · PhoreMost raised £11M ($15M) in a series A round in 2024, after which the Company expanded its SITESEEKER capabilities in both target discovery and drug …
WebOct 18, 2024 · UK-based biopharmaceutical company Phoremost and AI driven pharmatech XtalPi, have signed an agreement to identify and develop compounds to advance a drug discovery program against targets that epigenetically regulate tumour progression and which have been previously classified as ‘undruggable’. prairie city oregon community centerWebMar 23, 2024 · Dr Chris Torrance, CEO of PhoreMost Credit: PhoreMost A Cambridge University spin-out company which is working to create drugs to help cure cancer and … schwinn 100th anniversary cruiserWebPhoreMost is managed by a highly experienced commercial team and supported by world-renowned experts in oncology, biochemistry, and drug discovery. Dr. Chris Torrance was a founder of Horizon Discovery (LSE: HZD), which completed its IPO in March 2014, raising £37.8 million of new money. schwinn 103 stationary exercise bikeWebOver 10 years experience in implementing, troubleshooting, and enhancing PeopleSoft Absence Management. Lots of public sector … schwinn 105p partsWebChris Torrance is the Co-Founder and CEO at PhoreMost. Additionally, Chris Torrance has had 2 past jobs including Founder and Chief Scientific Officer at Horizon Discovery. PhoreMost Co-Founder and CEO Board and Advisor Roles Number of Current Board & Advisor Roles 1 Chris Torrance is the Scientific Advisor at Axol Bioscience. prairie commons library direct phone numberWebJan 7, 2024 · Dr Chris Torrance, CEO of PhoreMost, said: “We are delighted that Boehringer Ingelheim has chosen to work with PhoreMost to enhance its drug discovery pipeline with attractive biological ... schwinn 105p stationary exercise bikeWebMar 23, 2024 · PhoreMost raised £11M ($15M) in a series A round in 2024, after which the Company expanded its SITESEEKER capabilities in both target discovery and drug discovery. Dr Chris Torrance CEO,... prairie communications winnipeg